Affiliation:
1. Institute “Medical Academy named S.I. Georgievsky” FGAOU VO “V.I. Vernadsky Crimean Federal University”
Abstract
Background: attention deficit hyperactivity disorder (ADHD) is one of the urgent problems of psychoneurology. ADHD has a significant impact on the quality of life of a patient of any age. The variability of clinical manifestations depending on the age of the patient remain the subject of scientific discussion.The aim of the review: based on the scientific data of recent years, to study achievements in the field of diagnosis and rational choice of drugs used for the purpose of pharmacotherapy of patients of various age categories with ADHD.Materials and methods: the review is formed on the basis of scientific articles published in international databases (PubMed, Cochrane Library, Cyberleninka). The search was carried out using the following keywords: “attention deficit hyperreactivity syndrome”, “ADHD”, “psychostimulants”, “psychotropic drugs without psychoanaleptic effect”.Conclusion: the features of the development and evolution of ADHD over time, by the time the patient grows up, determine its clinical manifestations, they become more heterogeneous, which requires additional diagnostic efforts to clarify the diagnosis in order to select effective pharmacotherapy in combination with psychosocial methods of treatment. Currently, drugs with and without psychoanaleptic effect are used as drug therapy for ADHD. The most promising drugs for the treatment of ADHD are monoaminergic reuptake inhibitors, as well as drugs with melatonergic activity. Of considerable interest is the further study of drugs that affect the GABA system, glutamatergic and cannabinoid transmission in the brain. In general, the authors of analysed publications unanimously recognize that the problem of selecting effective therapy of ADHD in childs and adult patients requires further study and the proposal of new means of correction.
Publisher
Medical Informational Agency Publishers
Subject
Biological Psychiatry,Psychiatry and Mental health,Clinical Psychology
Reference56 articles.
1. Terán PA. Trastorno por déficit de atención/hiperactividad y uso de sustancias. Evidencias cientí-cas [Attention-deficit/hyperactivity disorder and substance abuse. Scientific evidence]. Medicina. 2020;80(2):76–79. (In Spanish). URL: https://www.medicinabuenosaires.com/revistas/vol80-20/s2/76.pdf
2. Stanton KJ, Denietolis B, Goodwin BJ, Dvir Y. Childhood Trauma and Psychosis: An Updated Review. Child Adolesc Psychiatr Clin N Am. 2020;29(1):115–129. doi: 10.1016/j.chc.2019.08.004 PMID: 31708041.
3. Giuppoi G, Giordano G, Maniscalco I, Erbuto D, Berardelli I, Conca A, Lester D, Girardi D, Pompili M. Suicide risk in attention-defecit/hyperactivity disorder. Psychiatria Danubina. 2018;30(1):2–10. doi: 10.24869/psyd.2018.2
4. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562–575. doi: 10.1038/s41380-018-0070-0 PMID: 29892054; PMCID: PMC6477889.
5. Eck SR, Xu SJ, Telenson A, Duggan MR, Cole R, Wicks B, Bergmann J, Lefebo H, Shore M, Shepard KA, Akins MR, Parikh V, Heller EA, Bangasser DA. Stress Regulation of Sustained Attention and the Cholinergic Attention System. Biol Psychiatry. 2020;88(7):566–575. doi: 10.1016/j.biopsych.2020.04.013 Epub 2020 Apr 28. PMID: 32600739; PMCID: PMC7487022.